Company news

Bright Minds Biosciences Inc. news in 2025

Bright Minds Biosciences Inc.'s news releases, calls and decks from 2025, newest first.

View company

CSE Bulletin: MOC Eligibility Update

November 27, 2025

Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting

November 25, 2025

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)

November 17, 2025

Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH

November 6, 2025

Bright Minds Biosciences to Present at Upcoming Conferences

October 30, 2025

Bright Minds Biosciences announces at-the-market offering

September 4, 2025

Bright Minds Biosciences Announces BMB?201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model

September 4, 2025

Bright Minds Biosciences to Present at Upcoming Conferences

August 25, 2025

Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

May 28, 2025

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

May 20, 2025

Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101

May 13, 2025

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

April 28, 2025

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

March 4, 2025

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

February 24, 2025

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

January 7, 2025

Decks in 2025